Jump to content

Fasoracetam

From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by Buddhafinder (talk | contribs) at 22:00, 10 June 2017 (Reinforced the content with secondary sources, made sure that no medical claims were made, only used primary references to enhance understanding of context. ~~~~). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Fasoracetam
Names
IUPAC name
(5R)-5-(piperidine-1-carbonyl) pyrrolidin-2-one
Other names
(5R)-5-oxo-D-prolinepiperidinamide
Identifiers
3D model (JSmol)
ChEMBL
ChemSpider
KEGG
  • InChI=1S/C10H16N2O2/c13-9-5-4-8(11-9)10(14)12-6-2-1-3-7-12/h8H,1-7H2,(H,11,13)/t8-/m1/s1 checkY
    Key: GOWRRBABHQUJMX-MRVPVSSYSA-N checkY
  • InChI=1/C10H16N2O2/c13-9-5-4-8(11-9)10(14)12-6-2-1-3-7-12/h8H,1-7H2,(H,11,13)/t8-/m1/s1
    Key: GOWRRBABHQUJMX-MRVPVSSYBL
  • O=C(N1CCCCC1)[C@@H]2NC(=O)CC2
Properties
C10H16N2O2
Molar mass 196.250 g·mol−1
Pharmacology
Oral
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
☒N verify (what is checkY☒N ?)

Fasoracetam (NS-105, 5-oxo-D-prolinepiperidinamide monohydrate[1], AEVI-001, LAM 105, MDGN-001, NFC 1[2]) is a research chemical of the racetam family.[3] It is a nootropic, and has been in a clinical trial for attention deficit hyperactivity disorder.[4]

In in vitro studies on mouse neurons, fasoracetam modulated mGluR II/III activity.[5] In studies in rats, it blocked memory disruptions caused by baclofen, a GABAB agonist[6] and upregulated production of GABAB receptors after repeat dosing.[7]

Clinical Trials

Fasoracetam was originally developed for use in the treatment of dementia, but was abandoned in Phase 3 clinical trials.[8] A Phase one safety study found a positive effect with 30 adolescents with ADHD and genetic disorders impacting metabotropic glutamate receptors (mGluRs).[9][10][11] Aevi Genomic Medicine (formerly Medigenics[12]), an emerging pharmaceutical firm, acquired the rights to develop this medication as of September, 2015. The company described fasoracetam as "a first-in-class non-stimulant, metabotropic glutamate receptor modulator."[13] Medgenics announced a phase 2/3 clinical trial in June, 2016,[14] from which results were released in March, 2017.[15] In spite of what the market viewed as negative results,[16] the company annonced plans for a Phase 2 clinical trial in the second half of 2017.[17]

References

  1. ^ FDA/NIH Substance registration system. Page accessed March 21, 2016
  2. ^ "Drug Profile Fasoracetam".
  3. ^ "5-oxo-D-prolinepiperidinamide monohydrate - Compound Summary". Retrieved 21 July 2013.
  4. ^ "Drug Profile Fasoracetam".
  5. ^ Oka, M; Itoh, Y; Tatsumi, S; Ma, FH; Ukai, Y; Yoshikuni, Y; Kimura, K. "A novel cognition enhancer NS-105 modulates adenylate cyclase activity through metabotropic glutamate receptors in primary neuronal culture". Naunyn Schmiedebergs Arch Pharmacol. 356: 189–96. doi:10.1007/pl00005040. PMID 9272724..
  6. ^ Ogasawara, T; Itoh, Y; Tamura, M; Mushiroi, T; Ukai, Y; Kise, M; Kimura, K. "Involvement of cholinergic and GABAergic systems in the reversal of memory disruption by NS-105, a cognition enhancer". Pharmacol Biochem Behav. 64: 41–52. doi:10.1016/s0091-3057(99)00108-2. PMID 10494996.
  7. ^ Shimidzu, T; Itoh, Y; Oka, M; Ishima, T; Ukai, Y; Yoshikuni, Y; Kimura, K. "Effect of a novel cognition enhancer NS-105 on learned helplessness in rats: possible involvement of GABA(B) receptor up-regulation after repeated treatment". Eur J Pharmacol. 338: 225–32. doi:10.1016/s0014-2999(97)81925-5. PMID 9424016.
  8. ^ Connolly, J; Glessner, J; Kao, C; Elia, J; Hakonarson, H. "ADHD & Pharmacotherapy: Past, Present and Future: A Review of the Changing Landscape of Drug Therapy for Attention Deficit Hyperactivity Disorder". Ther Innov Regul Sci. 49(5): 632–642. doi:10.1177/2168479015599811.
  9. ^ "Pediatric ADHD Study Shows Rare Genetic Mutation Underlies Condition in Some Patients". Duke Initiative for Science & Society.
  10. ^ Jones, G; Dejesus-Rosario, N; Kao, C; Larsen, L; Chiavacci, R; Pallotto, A; Kurian, C (2015). Exploratory Dose-Escalation Study of NFC-1 in ADHD Adolescents With Glutamatergic Gene Network Variants. American Academy of Child and Adolescent Psychiatry.
  11. ^ ClinicalTrials.gov. "Efficacy and Safety of NFC-1 in Adolescents With Genetic Disorders Impacting mGluR and ADHD".
  12. ^ "Medgenics, Inc. Announces Name Change to Aevi Genomic Medicine, Inc". MarketWired. {{cite web}}: Check |url= value (help)
  13. ^ Sharma, B. "Medgenics: NFC-1 Could Be A Key Future Revenue Driver".
  14. ^ "Medgenics Announces Enrollment of First Patient in Phase 2/3 Clinical Trial of NFC-1 in Adolescents With mGluR Mutation Positive ADHD". MarketWired.
  15. ^ "Drug Profile Fasoracetam".
  16. ^ [Why Aevi Genomic Medicine Got Crushed Today "Why Aevi Genomic Medicine Got Crushed Today"]. {{cite web}}: Check |url= value (help)
  17. ^ "MAevi Genomic Medicine Announces Plans to Initiate Phase 2 Clinical Trial to Confirm Genetic Responders to AEVI-001 and First Quarter 2017 Operating Results".


Stub icon

This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it.

Retrieved from "https://en.wikipedia.org/enwiki/w/index.php?title=Fasoracetam&oldid=784963873"